Requests for Medical Information. Eagle shall have the exclusive right and obligation to respond, in accordance with Applicable Laws and the Codes (as applicable), to all questions or requests for information about any Product that are outside of the Label made by any Healthcare Professional, Healthcare Organization or any other Third Party to the CAMs or other Spectrum Personnel (each, a “Product Information Request” or “PIR”). With respect to a Product Information Request received by a CAM or other Spectrum Personnel, such Spectrum Personnel shall promptly refer such PIRs to Eagle’s call center for response. For clarity, PIRs shall not be proactively solicited by CAMs or other Spectrum Personnel. For any PIR received by Spectrum’s call center, Spectrum shall promptly transfer such PIR to Eagle’s call center. Eagle shall promptly provide Spectrum with a copy of any written materials provided by Eagle in response to a PIR or a summary of any oral discussions provided by Eagle in response to a PIR.
Requests for Medical Information. Cardiome shall have the exclusive right and responsibility to respond to all questions and requests for information regarding Product received by the Sales Force or any MSL from prescribers or health care providers in the Territory in accordance with Commercialization Standards and Applicable Laws.
Requests for Medical Information. Sanofi shall have the exclusive right to respond to all questions or requests for information about the Co-Promotion Product(s) made by any medical professionals or any other Person to MyoKardia or its sales representatives that (a) warrant a response beyond the understanding or knowledge of such sales representative or (b) are beyond the scope of the product labeling or other Promotional Materials for such Co-Promotion Product(s) (each, a “PIR”). Upon MyoKardia’s request, Sanofi shall provide such PIR to MyoKardia at no cost to MyoKardia. MyoKardia shall, and shall cause its sales representatives to, promptly communicate to the Sanofi Information Center or Medical Resources Department all PIRs received by MyoKardia or such sales representatives. In connection with the Co-Promotion of the Co-Promotion Product(s), MyoKardia shall cause its sales representatives to inform prescribers and purchasers (if any) that they may contact the Sanofi Information Center regarding questions or requests for information about the Co-Promotion Product(s) by telephone or by completing a medical resource form and transmitting the completed form directly to Sanofi Medical Resources as provided on such form.
Requests for Medical Information. (a) AZ shall have the exclusive right to respond to all questions or requests for information about the Products made by any medical professionals or any other Person to the Company or a Representative that (i) warrant a response beyond the understanding or knowledge of the Representative or (ii) are beyond the scope of the Product Labels and Inserts or other Promotional Materials (a "PIR").
(b) The Company shall promptly communicate to the AZ Information Center or Medical Resources Department all PIRs received by the Company or Company Representatives. AZ shall provide to the appropriate Company representative, within a reasonable time after receiving or sending any such communication, copies of correspondence related to such PIR.
(c) In connection with the Promotion of the Products, the Company shall inform prescribers that they may contact the AZ Information Center regarding questions or requests for information about the Products by telephone or by completing a Medical Resource Form and faxing the completed form directly to AZ Medical Resources at the facsimile number provided on such form. AZ shall provide the Company with sufficient quantities of Medical Resource Forms and the Company shall provide such forms to prescribers.
Requests for Medical Information. (a) Notwithstanding anything in this Agreement or the Business Policies to the contrary, no Program Employee may respond to or otherwise communicate with any Target Prescriber or other Third Party with respect to any Off-Label Information []*.
(b) AstraZeneca shall have the exclusive right to respond in the ordinary course of its business, to all questions or requests for information about the Product made by any *Confidential Treatment Requested. Omitted portions filed separately with the Commission. medical professionals or any other Person to the Representatives or CSDs, that (i) warrant a response beyond the understanding or knowledge of the Representative or CSD, as applicable, or (ii) are outside the scope of the Product Labels and Inserts or the Promotional Materials (each, a “PIR”); provided that []*. Cubist shall promptly communicate all PIRs (other than any PIR for which a response is provided by a CSD pursuant to Section 3.8(a)) to AstraZeneca as follows: by telephone at []* (or such other number as AstraZeneca may designate from time to time) (which unpublished number is not to be provided by Cubist to Third Parties), 8:00 a.m. – 6:00 p.m. ET, Monday through Friday, excluding holidays, or completing an electronic Web PIR Form at []*, or such other website address as AstraZeneca may designate from time to time. Cubist shall have the right at its option to include a hyperlink to such website address on Cubist’s internal website for the Product in a form and manner to be mutually agreed upon by the parties (such agreement not to be unreasonably withheld, conditioned or delayed). Cubist may also provide the following published number 0-000-000-0000 (or such other number as AstraZeneca may designate from time to time) to medical professionals (and any other Persons who make any PIRs) for such Persons to contact the AstraZeneca Information Center directly (provided that the foregoing shall not limit Cubist’s obligations set out above in this Section 3.8(b) with respect to any PIRs). Cubist may at its option require a signed document from any Person making an unsolicited inquiry before accepting the inquiry.
(c) In connection with the Program, including the Promotion of the Product, Cubist may inform Target Prescribers or other medical professionals that they may contact the AstraZeneca Information Center at 0-000-000-0000 (or such other number as AstraZeneca may designate from time to time) regarding questions or requests for information about the Pr...
Requests for Medical Information. 13.4.1 Abraxis shall have the exclusive right to respond to all questions or requests for information about the Product made by any medical professionals or any other Person to AstraZeneca or its Representatives that (i) warrant a response beyond the understanding or knowledge of such Representative or (ii) are beyond the scope of the Product Labels and Inserts or other Promotional Materials (a “PIR”).
13.4.2 AstraZeneca shall, and shall cause its Representatives to, promptly communicate to the Abraxis Information Center and/or Medical Resources Department all PIRs received by AstraZeneca or such Representatives.
13.4.3 In connection with the Promotion of the Products, AstraZeneca shall cause its Representatives to inform prescribers that they may contact the Abraxis Information Center regarding questions or requests for information about the Products by telephone or by completing a Medical Resource Form and faxing the completed form directly to Abraxis’ Medical Resources at the facsimile number provided on such form. Abraxis shall provide AstraZeneca with sufficient quantities of Medical Resource Forms and AstraZeneca shall cause the Representatives to provide such forms to prescribers.
Requests for Medical Information. (a) AstraZeneca shall have the exclusive right and responsibility to respond to all PIRs received by the Sales Force or any MSL.
(b) MDCO shall use Commercially Reasonable Efforts to promptly communicate to the AstraZeneca Information Center or Medical Resources Department all PIRs received by MDCO by contacting the AstraZeneca Information Center at 800-236-0000 xx xxxxleting an electronic Web PIR Form at https://xxxxxxxxx.xxxxxxxxxxx-xx.xxx/xxxxxxx.xxx, xx xxxh other website address as AstraZeneca may designate from time to time. Alternately, MDCO may offer to put the applicable Target Hospital Personnel in touch with the AstraZeneca Virtual Scientific Exchange Center (VSEC) at [**].
(c) In connection with the performance of the MDCO Agreement Activities, MDCO shall inform Target Hospitals that they may contact the AstraZeneca Virtual Scientific Exchange Center (VSEC) at [**] regarding questions or requests for medical information about the Product by telephone (in accordance with AstraZeneca's Policy on Scientific Exchange). MDCO shall report any Product Quality Complaints and Adverse Events in accordance with Section 9.1.
(d) By the thirtieth (30th) day after the end of each month during the Detailing Term, AstraZeneca shall provide a written report to MDCO in an electronic format reasonably acceptable to both Parties that contains a list of each PIR communicated to AstraZeneca by MDCO to which AstraZeneca responded during such month.
Requests for Medical Information. (i) Client shall have the exclusive right to respond to all questions or requests for information made to inVentiv or its Sales Representatives by any medical professionals or any other person or entity about the Product, if such questions or requests (i) warrant a response beyond the understanding or knowledge of the Sales Representative or (ii) are beyond the scope of the Product labels and inserts or Product Literature (a “Medical Information Request”).
(ii) inVentiv shall promptly communicate to Client, or any third-party vendor designated by Client to process such information, all Medical Information Requests received by inVentiv or the inVentiv Sales Representatives. If Client designates such a third-party vendor or † DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION changes such third-party vendor (which Client may do from time to time in its sole discretion), it shall notify inVentiv in writing of the name and contact information for such new vendor.
Requests for Medical Information. 13.4.1 Abraxis shall have the exclusive right to respond to all questions or requests for information about the Product made by any medical professionals or any other Person to AstraZeneca or its Representatives that (i) warrant a response beyond the understanding or knowledge of such Representative or (ii) are beyond the scope of the Product Labels and Inserts or other Promotional Materials (a “PIR”).
13.4.2 AstraZeneca shall, and shall cause its Representatives to, promptly communicate to the Abraxis Information Center and/or Medical Resources Department all PIRs received by AstraZeneca or such Representatives.
Requests for Medical Information. The Agreement is hereby amended so that Section 3.8(a) is deleted in its entirety and replaced with the following: “Notwithstanding anything in this Agreement or the Business Policies to the contrary, no Program Employee may respond to or otherwise communicate with any Target Prescriber or other Third Party with respect to any Off-Label Information []*.”
